Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359463 · ClinicalTrials.gov registry record · Phase 1
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00359463 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 33 participants.
The verdict
NCT00359463, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.
Interventions
- DRUG eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-04-18 |
| Est. Completion | 2007-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359463
The ClinicalTrials.gov registry entry for NCT00359463 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eltrombopag is the first listed.
NCT00359463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359463 about?
NCT00359463 is a clinical study titled "Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment". The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those...
What is the current status of trial NCT00359463?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2006-04-18. Estimated completion is 2007-03-07.
What interventions are being tested in trial NCT00359463?
The interventions under investigation include: eltrombopag (DRUG).
Who is sponsoring clinical trial NCT00359463?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.